NECA recently attended a Rare Cancers Roundtable to discuss u201cThe value of cancer clinical trials and setting up for success.u201d
Attendees were diverse, including industry, researchers, patient organisations, patients, clinicians, Clinical Trials Australia, Medicines Australia and the NSW Cancer Institute.
Presentations and panel discussions explored the Australian clinical trials landscape, protocols and ethics, the global pipeline, and how to spot and fast-track Australian access to global trials.
Following this, attendees broke into groups to discuss issues and gaps. They also brainstormed how trials could be increased, improved, and made more widely available in Australia. This is the first of three roundtables.
The ultimate aim is to ensure that we can and do participate in global trials and studies, and that Phase I, II and III trials are available not just for rare cancers, but for all cancers, with a particular focus on rare and less common cancers that can be subsets of more common ones.
